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Skeletal muscle is the major tissue for
the increased glucose disposal caused by
insulin or exercise. Each stimulus elevates
GLUT4 glucose transporter translocation to
skeletal muscle’s cell surface membranes,
but distinct signalling pathways lead to
this common outcome. Insulin’s proximal
signalling events include activation of
the insulin receptor, phosphatidylinositol
3-kinase, and Akt2. The signalling events
necessary for exercise-induced glucose
transport may involve increased cyto-
solic calcium, AMP-activated protein kinase
and other mechanisms. The prevalence
of obesity, insulin resistance and diabetes
provides motivation for understanding
the exercise pathway in humans because
in many insulin resistant conditions,
exercise-stimulated glucose transport is
normal, presenting an attractive therapeutic
target.
Recently, two related Rab-GTPase
activating proteins (GAPs) known as
TBC1D1 and TBC1D4 (also called Akt sub-
strate of 160 kDa or AS160) were recognized
to potentially link the proximal signalling
of insulin and/or exercise with GLUT4.
TBC1D4’s phosphorylation in response to
insulin was discovered by Gustav Lienhard’s
group using 3T3-L1 adipocytes and was
subsequently found in rat skeletal muscle
with insulin or contraction (Bruss et al.
2005). Reviewing TBC1D4’s relationship
with GLUT4 is helpful before considering
TBC1D1. Insulin’s activation of Akt2 causes
TBC1D4 phosphorylation on multiple
Akt phosphomotifs, thereby inhibiting
TBC1D4’s activation of Rab-GTPase
proteins associated with GLUT4 vesicles
and/or causing TBC1D4’s release
from GLUT4 vesicles. Insulin-induced
phosphorylation of TBC1D4 on key
insulin-responsive motifs enhances
TBC1D4’s association with 14-3-3 proteins,
which may regulate GLUT4 vesicle traffic.
Akt2 is not essential for exercise-stimulated
glucose transport, but mutation of four
phosphomotifs on TBC1D4 caused a
small reduction in contraction-stimulated
glucose uptake in mouse muscle. A
mutation in TBC1D4’s calmodulin binding
domain (CBD) also caused a modest
decline in glucose uptake with contraction,
but not with insulin. Simultaneous
mutation of the CBD and phosphomotifs
did not reduce contraction-stimulated
glucose uptake below the values found
with either mutation alone. These results
suggest a modest role for TBC1D4 in
contraction-stimulated glucose uptake,
but TBC1D4-independent mechanisms
(potentially involving TBC1D1) are likely
to be essential for most of the contraction’s
effect.
TBC1D1 and TBC1D4 have significant
sequence similarity, including a GAP
domain and a CBD. The sequence
surrounding a key Akt phospho-site of
TBC1D4 (T642) is nearly identical to the
sequence surrounding TBC1D1’s T596,
but TBC1D4 includes a greater number of
predicted Akt phosphomotifs. Although
AMPK can phosphorylate both proteins,
TBC1D1 includes an important AMPK
phosphomotif (Ser237) that TBC1D4
lacks. In L6 cells, Ser237 phosphorylation
of TBC1D1 is increased with AMPK
activation, but not by insulin. Preventing
the increase in Ser237 phosphorylation
by expressing mutated TBC1D1 in
HEK-293 cells blocks the AMPK-associated
increase in 14-3-3 binding by TBC1D1
(Chen et al. 2008). Insulin or electrically
simulated contractions enhances TBC1D1
phosphorylation on various sites in rodent
muscle, but only contraction elevates
phosphorylation on Ser237 (Funai et al.
2009). Contraction-stimulated (but not
insulin-stimulated) glucose uptake was
partially reduced in muscle of mice
expressing TBC1D1 mutated on four
phosphomotifs (including Ser231, homo-
logous to human Ser237) (An et al. 2010).
Evidence from cells and rodent muscle links
TBC1D1 Ser237 phosphorylation to both
14-3-3 binding and contraction-stimulated
(but not insulin-stimulated) glucose
transport. But is this relevant to
humans?
The results of the study by Frøsig et al.
(2010) in this issue of The Journal of
Physiology fill an important gap in the
TBC1D1 story by demonstrating that
in vivo exercise (cycle ergometery) by
humans can increase the phosphorylation of
skeletal muscle TBC1D1 on the key Ser237
site. The increased Ser237 phosphorylation
occurred with each of three protocols
which involved a nearly 3-fold range of
work-rates (222–658 W) and 40-fold range
of duration (0.5–20 min). Furthermore,
TBC1D1’s capacity for 14-3-3 binding
was increased in muscle by each exercise
protocol. The exercise effects on Ser237
phosphorylation and 14-3-3 binding were
rapid and sustained, as would also be
expected for exercise-stimulated glucose
transport.
What is the mechanism for increased
phosphorylation of Ser237-TBC1D1 after
exercise? There is not a straightforward
experimental approach for directly
answering this question in humans under-
going in vivo exercise. Accordingly, Frøsig
et al. used mice to probe the specific
roles of AMPK isoforms in contraction-
induced Ser237 phosphorylation. Studying
α1- and α2-AMPK knockout mice and
wild-type controls, they demonstrated
that contraction-stimulated Ser237
phosphorylation was unaltered in mice
deficient in α1, but greatly diminished
in muscles from mice lacking α2.
Earlier research demonstrated that
α2-AMPK knockout mice compared
to wild-type controls have normal
contraction-stimulated glucose transport,
but it is uncertain if the residual contraction
effect on Ser237 in α2-knockout mice
plays a role in contraction-mediated
glucose transport. It is also unknown
if the residual Ser237 phosphorylation
in α2-knockout mice is attributable to
a compensatory increase in α1-AMPK
activity or to another kinase. A recent
publication found that electrically
stimulated muscle contractions activated
an AMPK-related kinase known as sucrose
non-fermenting AMPK-related kinase
(SNARK), and that a mutation of SNARK
that attenuated contraction-stimulated
SNARK activity was accompanied by
decreased contraction-stimulated glucose
transport (Koh et al. 2010). Furthermore,
exercise by humans similar to the 2 and
20 min protocols used by Frøsig et al. also
activated skeletal muscle SNARK. However,
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the effect of SNARK on TBC1D1 Ser237
phosphorylation remains to be assessed.
What will future chapters of the TBC1D1
story reveal? Do α2-AMPK and/or SNARK
regulate Ser237 phosphorylation in human
skeletal muscle? Is Ser237 phosphorylation
necessary for exercise-induced glucose
transport in human skeletal muscle?
Does TBC1D1’s CBD participate in
exercise-stimulated glucose transport? Do
exercise effects on TBC1D1 have functional
roles other than increased glucose trans-
port? The TBC1D1 story is far from
finished.
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